Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02, FiscalAI reports. The company had revenue of $371.07 million for the quarter, compared to analyst estimates of $365.76 million. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%.
Here are the key takeaways from Guardian Pharmacy Services’ conference call:
- Guardian raised 2026 guidance to revenue of $1.44 billion–$1.46 billion and Adjusted EBITDA of $136 million–$138 million. Third-quarter Adjusted EBITDA rose 24% year over year to $33.9 million, while net income nearly doubled to $19 million.
- Reported revenue fell 1.7% to $371 million, primarily due to IRA-related drug price reductions; management said revenue would have grown at a high-single-digit rate without that impact. Prescription volume increased 10% year over year.
- Growth efforts include new pharmacy locations and acquisitions, including Nautilus, whose residents were transitioned to Guardian pharmacies and whose deal is expected to be accretive after onboarding costs. Management said its acquisition pipeline remains active and sees room to expand through both acquisitions and greenfield openings.
- Management cited improving assisted-living occupancy, complex resident care needs, and Guardian’s estimated 14% share of its primary market as support for continued growth. It said service quality and facility wins—not occupancy alone—are central to expanding the business.
- Guardian is working with payers on reimbursement that better reflects its services and generic-drug mix, which management believes could improve the business’s long-term stability. The company ended the quarter with about $120 million in cash and no debt.
Guardian Pharmacy Services Price Performance
Shares of NYSE:GRDN traded up $2.58 during mid-day trading on Friday, hitting $42.45. The company had a trading volume of 1,085,464 shares, compared to its average volume of 383,960. The firm has a fifty day moving average price of $41.42 and a 200 day moving average price of $38.30. The company has a market capitalization of $2.11 billion, a PE ratio of 36.28, a price-to-earnings-growth ratio of 2.09 and a beta of 0.06. Guardian Pharmacy Services has a one year low of $26.34 and a one year high of $48.33.
Analysts Set New Price Targets
A number of research firms have weighed in on GRDN. Oppenheimer increased their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Truist Financial upped their price objective on shares of Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Wall Street Zen lowered shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research note on Sunday, October 25th. Weiss Ratings cut shares of Guardian Pharmacy Services from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Finally, KeyCorp assumed coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, September 22nd. They set an “overweight” rating and a $52.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.57.
Read Our Latest Analysis on GRDN
Guardian Pharmacy Services Company Profile
Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.
The company’s services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents’ medication regimens.
Featured Stories
- Five stocks we like better than Guardian Pharmacy Services
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
